Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0UPSLG
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
M69-MMAE
|
|||||
| Synonyms |
M69-MMAE (ADC); M69 MMAE
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Mantle cell lymphoma [ICD11:2A85]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3.5
|
|||||
| Antibody Name |
Anti-Matriptase mAb M69
|
Antibody Info | ||||
| Antigen Name |
Suppressor of tumorigenicity 14 protein (ST14)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
Vedotin
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 82.10% (Day 18) | Positive ST14 expression (ST14+++/++) | ||
| Method Description |
Five thousand cells per well were plated in RPMI 1,640 media supplemented with 10% FBS. After overnight culture, media was removed and fresh media containing the ADC was added and incubated for different time periods.
|
||||
| In Vitro Model | Mantle cell lymphoma | JeKo-1 cells | CVCL_1865 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 5.29 ug/mL±0.28 ug/mL | Positive ST14 expression (ST14+++/++) | ||
| Method Description |
Five thousand cells per well were plated in RPMI 1,640 media supplemented with 10% FBS. After overnight culture, media was removed and fresh media containing the ADC was added and incubated for different time periods.
|
||||
| In Vitro Model | Mantle cell lymphoma | Mino cells | CVCL_1872 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 7.20 ug/mL±2.01 ug/mL | Positive ST14 expression (ST14+++/++) | ||
| Method Description |
Five thousand cells per well were plated in RPMI 1,640 media supplemented with 10% FBS. After overnight culture, media was removed and fresh media containing the ADC was added and incubated for different time periods.
|
||||
| In Vitro Model | Mantle cell lymphoma | MAVER-1 cells | CVCL_1831 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 7.69 ug/mL±0.29 ug/mL | Positive ST14 expression (ST14+++/++) | ||
| Method Description |
Five thousand cells per well were plated in RPMI 1,640 media supplemented with 10% FBS. After overnight culture, media was removed and fresh media containing the ADC was added and incubated for different time periods.
|
||||
| In Vitro Model | Mantle cell lymphoma | Z-138 cells | CVCL_B077 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 13.78 ug/mL±2.15 ug/mL | Positive ST14 expression (ST14+++/++) | ||
| Method Description |
Five thousand cells per well were plated in RPMI 1,640 media supplemented with 10% FBS. After overnight culture, media was removed and fresh media containing the ADC was added and incubated for different time periods.
|
||||
| In Vitro Model | Mantle cell lymphoma | JeKo-1 cells | CVCL_1865 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.